title: Genetics of allergic disease.
abstract: Currently, more than 20.3 million Americans report having asthma and an even greater number suffer from allergies. The cost for treatment of these dis-eases in the United States is greater than $8 billion with more than 40% of this total representing drug expenditure [59]. An intense effort has been made to understand the genetic components of asthma and allergies and how the identified genetic differences influence disease progression and response to drugs. In the future, it will be possible in the clinical setting to analyze a patient's genetic repertoire. From this information, the physician will gain in-sight into the genes involved in producing that subject's allergic and asthmatic phenotype; understand the natural history of that patient's disease;and predict responses (positive and negative) to pharmacologic agents. The end result will be the ability to tailor a specific treatment regime for each patient and reduce the overall cost of health care related to allergies and asthma.
authors.affiliation: Asthma and Allergic Disease Center, Beirne Carter Center for Immunology Research, University of Virginia Health Systems, Charlottesville, VA 22908-1355, USA.
authors.forename: John W
authors.initials: JW
authors.lastname: Steinke
authors.forename: Larry
authors.initials: L
authors.lastname: Borish
mesh_terms: D001249:Asthma / Q000150:complications / Q000188:drug therapy / Q000235:genetics*; D018946:Chemokine CCL5; D019742:Chemokines, CC / Q000235:genetics; D006239:Haplotypes / Q000235:genetics; D006801:Humans; D006967:Hypersensitivity / Q000150:complications / Q000188:drug therapy / Q000235:genetics*; D007378:Interleukins / Q000235:genetics; D018950:Lipopolysaccharide Receptors / Q000235:genetics
chemical_list: C483024:CCL5 protein, human; D018946:Chemokine CCL5; D019742:Chemokines, CC; D007378:Interleukins; D018950:Lipopolysaccharide Receptors